North America Genome Editing Market

The genome editing market in North America is expected to grow from US$ 2,136.41 million in 2021 to US$ 7,024.71 million by 2028; it is estimated to grow at a CAGR of 18.5% from 2021 to 2028.

Over the past few years, advances in genome editing technologies have been making constant headlines. Genome editing technologies can alter biological research and significantly impact human health, food security, and environmental sustainability since they are precise, relatively inexpensive, easy to use, and remarkably powerful. The advances in genome editing can be traced back to quiet beginnings in the 1990s. The introduction of CRISPR-Cas9—a genome-editing tool that can be used to make precise and targeted changes in the DNA sequence with ease—is mainly responsible for the recent rise in the amount and scope of applications of genome editing technologies. The CRISPR platform's ease of use, as compared to previous technologies, has resulted in its widespread adoption and application. Genome editing could have a favorable impact on sustainable development, environmental management, food security, and the introduction of affordable diagnostics and therapies for various diseases due to these advancements. A team from MIT and Harvard's Broad Institute has developed a novel CRISPR genome-editing technique that has the potential to fix up to 89% of disease-causing genetic abnormalities. CRISPR-Cas9 and reverse transcriptase, two of the most significant proteins in molecular biology, have been merged into a single machine by researchers. Prime editing is a method that can alter human cells directly in a precise, efficient, and highly versatile manner. They have also developed a CRISPR RNA-cutting enzyme into an antiviral agent that can be programmed to detect and eliminate RNA-based viruses in human cells. The Cas13 enzyme has previously been used to cut and alter human RNA and as a diagnostic approach for detecting the presence of viruses, bacteria, and other targets. This is one of the first studies to use Cas13, or any CRISPR system, as an antiviral in human cells in culture. Recognizing the potential of genome editing techniques for studying and manipulating the genome, the DBT has been fostering research and innovation in genome engineering technologies and applications to make them more accessible and inexpensive for research and development (R & R&D). Through focused calls for proposals in different areas such as the development of new methods, tools, processes, and platforms for genome editing, improvement of existing genome-editing methods, and novel applications of genome editing technologies in agriculture, bioenergy, environmental research, and human health, efforts have been made to encourage R&D programs in emerging genome engineering technologies and their applications. Despite contributing to one-third of all deaths worldwide, there is no effective treatment, to date, for fibrosis. This study has established PAI-1 as a novel drug target, and pharmacologically targeting this protein may be an effective treatment for combating fibrosis. These factors for CRISPR system research are likely to favor the market's growth.

In the North American region, the US was profoundly affected by the outbreak of the COVID-19 pandemic. The country has marked the highest number of positive patients. Across the nation, various healthcare research centers were working only for research on COVID 19 therapeutics. As the crisis moved forward, healthcare professionals realized that developing novel therapies using innovative technologies is essential to mitigate this unprecedented crisis. In the middle of this situation, governments around the world were not prepared for such a pandemic. The treatment against COVID 19 has been established. Hence, the lack of definitive therapy offers significant opportunities for the genome editing-related market as US FDA has recently approved the use of plasma therapy for critically ill COVID 19 patients. Upcoming stem cell therapies to boost patients' immune systems and eliminate the virus will offer significant growth prospects for the market. For instance, Lattice Biologics, in collaboration with Alumina Partners, has been accelerating phase 1 clinical trials for its stem cell-based AminioBoost therapies of COVID-19. Moreover, the mRNA-based vaccines against the COVID19 have been given emergency use authorization by the regulatory agencies in the region. The active involvement of the government and the associated market players in exploring opportunities for genome editing-related products and services is expected to drive such developments which will add to the future demand for the genome editing market in the North American region.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America genome editing market. The North America genome editing market is expected to grow at a good CAGR during the forecast period.

North America Genome Editing Market Revenue and Forecast to 2028 (US$ Million)  

North America Genome Editing Market Segmentation

North America Genome Editing Market – By Technology

• CRISPR
• TALEN
• Antisense
• Other

North America Genome Editing Market – By Application

• Cell Line Engineering
• Genetic Engineering
• Diagnostic Applications
• Drug Discovery
• Others

North America Genome Editing Market – By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Clinical Research Organizations (CRO's)

North America Genome Editing Market – By Country

• US
• Canada
• Mexico

North America Genome Editing Market – Companies Mentioned

• THERMO FISHER SCIENTIFIC INC.
• MERCK KGaA
• Lonza
• Horizon Discovery Group plc.            
• Integrated DNA Technologies         
• GenScript
• New England Biolabs
• Eurofins Scientific
• CRISPR Therapeutics
• Editas Medicine

North America Genome Editing Market Strategic Insights

North America Genome Editing Market Segmentation Analysis

North America Genome Editing Market Report Highlights

North America Genome Editing Report Scope

North America Genome Editing Market Country and Regional Insights